Last reviewed · How we verify
COPPEBVCAD vs BEACOPP vs ABVD
COPPEBVCAD, BEACOPP, and ABVD are combination chemotherapy regimens that use multiple cytotoxic agents to kill rapidly dividing cancer cells.
COPPEBVCAD, BEACOPP, and ABVD are combination chemotherapy regimens that use multiple cytotoxic agents to kill rapidly dividing cancer cells. Used for Hodgkin lymphoma (early-stage and advanced-stage).
At a glance
| Generic name | COPPEBVCAD vs BEACOPP vs ABVD |
|---|---|
| Sponsor | Gruppo Italiano Studio Linfomi |
| Drug class | Polychemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These are polychemotherapy regimens used in lymphoma treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are established Hodgkin lymphoma treatments. COPPEBVCAD appears to be a variant combining elements of these regimens. They work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.
Approved indications
- Hodgkin lymphoma (early-stage and advanced-stage)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Pulmonary toxicity
- Infertility
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COPPEBVCAD vs BEACOPP vs ABVD CI brief — competitive landscape report
- COPPEBVCAD vs BEACOPP vs ABVD updates RSS · CI watch RSS
- Gruppo Italiano Studio Linfomi portfolio CI